Type 2 & other diabetes

Triglycerides and risk of cardiovascular events in statin-treated patients with newly diagnosed type 2 diabetes: a Danish cohort study

Cardiovasc DiabetolPublished Population-based cohort study

Authors' conclusion

In statin-treated patients with newly diagnosed T2DM, triglyceride levels are associated with MACE already from 1.0 mmol/L. This suggests that high triglyceride levels are a predictor of residual cardiovascular risk in early T2DM and could be used to guide allocation of additional lipid-lowering therapies for CVD prevention.

Study context

Population
Statin-treated, CVD-naïve patients with newly diagnosed T2D, Northern Denmark 2005–2017; triglycerides assessed within 1 year of diagnosis; median age 63 years, 53% males
Participants
27,080 participants
Exposure
Triglyceride levels on statin vs <1.0 mmol/L
Outcome
MACE: composite of MI, ischemic stroke or cardiac death
Follow-up
From 1 year after T2D diagnosis until 30 April 2021
Methodological detailsCox regression adjusted for confounders
  • Cox regression adjusted for confounders

Main finding

As reported in the abstract

Incident MACE
Adjusted hazard ratio (95% CI)
1.0-1.9 mmol/Lvs <1.0 mmol/L
1.14(1.00–1.29)
2.0-2.9 mmol/Lvs <1.0 mmol/L
1.30(1.12–1.51)
≥3.0 mmol/Lvs <1.0 mmol/L
1.44(1.20–1.73)
Incident major cardiovascular events (MACE) events overall
1,957 (11.0 per 1000 person-years)

Observational data: associations, not effects.

Further findings

MACE components and LDL-C adjustment

Association primarily driven by higher rates of MI and cardiac death; attenuated only slightly after additional adjustment for LDL-C

Spline analyses

Linearly increasing risk of MACE with higher triglyceride levels

MACE by sex (stratified analyses)

Associations between triglyceride levels and MACE stronger among women

Original publication

Triglycerides and risk of cardiovascular events in statin-treated patients with newly diagnosed type 2 diabetes: a Danish cohort study. Cardiovasc Diabetol. Published 26 July 2023. doi:10.1186/s12933-023-01921-5

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.